∙ Participants are eligible to be included in the study only if all of the following criteria apply:

• Male or female participants aged 18 to 75 years at the time of signing the ICF

• Confirmed diagnosis of CD for at least 3 months prior to Baseline

• Confirmed diagnosis of moderate to severe CD as assessed by:

‣ Crohn's Disease Activity Index (CDAI) score and the Simple Endoscopic Score for Crohn's disease (SES-CD) on an endoscopy confirmed by a central reader

⁃ stool frequency (SF), abdominal pain (AP) score

• History of prior exposure to standard treatment (5-ASA, steroids, immunomodulators or antibiotics) or advanced therapies (biologics or small molecules), but having inadequate response to, loss or response to or intolerance to at least one of these therapies

• On stable doses of standard treatments prior to screening (Oral 5-ASA compounds, Oral corticosteroids, AZA, 6-MP, or MTX ..)

• Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Women participants should not be pregnant or breastfeeding.